NovaBay Pharmaceuticals Signs Distribution Agreement to Make Avenova Available in New Zealand

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:

), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that the company's breakthrough prescription daily eyelid and lash hygiene product, Avenova™, will be marketed in New Zealand through a partnership with Ophthalmic Instrument Company. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150902005433/en/ Ophthalmic Instrument Company (OIC) is the leading supplier of diagnostic and surgical products to the ophthalmology and optometry sectors in New Zealand. "This new agreement is part of our strategy to make Avenova available around the world," said Ron Najafi, Ph.D., President and CEO of NovaBay. "We are already in China, Southeast Asia and the Middle East. Now, patients in New Zealand will be able to get the benefits of this important product." Avenova is the only lid & lash product containing Neutrox. Neutrox is NovaBay's proprietary pure hypochlorous acid without any sodium hypochlorite impurities. Hypochlorous acid is naturally produced by white blood cells to fight microbial invaders. Lab tests show that NovaBay's proprietary formulation of hypochlorous acid is effective in solution both at killing microbes and at neutralizing the bacterial enzymes and toxins that contribute to common eye conditions like blepharitis, meibomian gland dysfunction and associated dry eye. Patients and doctors report that a regimen of daily lid hygiene using Avenova has been able to finally bring relief to people suffering from these often-painful conditions.